Tumor Related Endocrine and Neuroendocrine Disorders

Mission Statement

Cancer affects approximately 1 in 285 children before the age of 20, and advances in oncology have created a growing population of patients whose care increasingly depends on expertise at the intersection of endocrinology and cancer. From endocrine and neuroendocrine tumors and hereditary cancer predisposition syndromes to the endocrine consequences of cancer therapies during treatment and throughout survivorship, these disorders represent some of the most complex and rapidly evolving challenges in pediatric endocrinology.

The Pediatric Endocrine Society’s Tumor Related Endocrine and Neuroendocrine Disorders (TREND) Special Interest Group is dedicated to advancing excellence in the care of these patients through education, collaboration, mentorship, and the exchange of collective knowledge and experience. We bring together clinicians, researchers, educators, and trainees to improve understanding, foster innovation, and advance evidence-based care across the full spectrum of tumor-related endocrine and neuroendocrine disorders.

Endocrine issues include:

• Growth hormone deficiency and other anterior pituitary hormone deficiencies
• Precocious puberty
• Primary hypothyroidism
• Thyroid nodules and cancer
• Adrenal insufficiency
• Gonadal dysfunction
• Decreased bone mineral density
• Obesity
• Dyslipidemia
• Insulin resistance
• Diabetes.

A systematic approach whereby survivors are screened for endocrine late effects based on their medical history and treatment exposures may improve health outcomes by allowing the early detection and treatment of these complications. The PES Tumor Related Endocrine and Neuroendocrine Disorders (“TREND”) SIG aims to improve dissemination of knowledge, increase awareness, and establish mechanisms for research and clinical collaborations.